ATE432997T1 - Therapieüberwachung für tumoren unter benutzung acc133 mrna - Google Patents

Therapieüberwachung für tumoren unter benutzung acc133 mrna

Info

Publication number
ATE432997T1
ATE432997T1 AT05710924T AT05710924T ATE432997T1 AT E432997 T1 ATE432997 T1 AT E432997T1 AT 05710924 T AT05710924 T AT 05710924T AT 05710924 T AT05710924 T AT 05710924T AT E432997 T1 ATE432997 T1 AT E432997T1
Authority
AT
Austria
Prior art keywords
disease
amount
treatment
individual
acc133
Prior art date
Application number
AT05710924T
Other languages
English (en)
Inventor
Maarten Penning
Den Broek Sebastiaan Van
Emile Voest
Laurens Beerepoot
Niven Mehra
Original Assignee
Primagen Holding Bv
Umc Utrecht Holding Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Primagen Holding Bv, Umc Utrecht Holding Bv filed Critical Primagen Holding Bv
Application granted granted Critical
Publication of ATE432997T1 publication Critical patent/ATE432997T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/142Toxicological screening, e.g. expression profiles which identify toxicity
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT05710924T 2004-03-02 2005-03-02 Therapieüberwachung für tumoren unter benutzung acc133 mrna ATE432997T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US54945004P 2004-03-02 2004-03-02
EP04075686A EP1571225A1 (de) 2004-03-02 2004-03-02 Diagnose von Krankheiten und Überwachung einer Therapie unter Verwendung des AC133 Gens
PCT/NL2005/000155 WO2005083123A1 (en) 2004-03-02 2005-03-02 Diagnosis of (a risk of) disease and monitoring of therapy

Publications (1)

Publication Number Publication Date
ATE432997T1 true ATE432997T1 (de) 2009-06-15

Family

ID=34746048

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05710924T ATE432997T1 (de) 2004-03-02 2005-03-02 Therapieüberwachung für tumoren unter benutzung acc133 mrna

Country Status (4)

Country Link
EP (2) EP1571225A1 (de)
AT (1) ATE432997T1 (de)
CA (1) CA2558604A1 (de)
WO (1) WO2005083123A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006037106A2 (en) * 2004-09-24 2006-04-06 Rfe Pharma Llc Carboxy-amido-triazoles for the localized treatment of ocular diseases
US20160106717A1 (en) 2004-09-24 2016-04-21 Gen Pharma Holdings LLC Cai-based systems and methods for the localized treatment of uveitis
WO2008003013A2 (en) * 2006-06-29 2008-01-03 Abbott Laboratories Antitumorigenic drug combination comprising an hdac inhibitor and a tsp-1 peptidomimetic
US20080027008A1 (en) * 2006-07-31 2008-01-31 Jack Henkin Antitumorigenic Drug Combination
US8802384B2 (en) 2009-03-12 2014-08-12 Boehringer Ingelheim International Gmbh Method or system using biomarkers for the monitoring of a treatment
WO2010123625A1 (en) * 2009-04-24 2010-10-28 University Of Southern California Cd133 polymorphisms predict clinical outcome in patients with cancer
JP6082737B2 (ja) * 2011-07-07 2017-02-15 リサーチ キャンサー インスティテュート オブ アメリカResearch Cancer Institute Of America がんを治療するためのシステム、方法、および製剤
US8933078B2 (en) 2011-07-14 2015-01-13 Research Cancer Institute Of America Method of treating cancer with combinations of histone deacetylase inhibitors (HDAC1) substances
US11890292B2 (en) 2017-02-27 2024-02-06 Research Cancer Institute Of America Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
WO2018170457A1 (en) 2017-03-17 2018-09-20 Research Cancer Institute Of America Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
WO2019099750A1 (en) 2017-11-17 2019-05-23 Research Cancer Institute Of America Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
KR102138249B1 (ko) * 2018-10-30 2020-07-27 서울대학교산학협력단 유방암 진단용 바이오마커 및 이의 용도

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ543940A (en) * 2000-12-04 2008-04-30 Primagen B V Determining the ratio of genomic DNA and mtDNA or their related gene products with regards to determining the stage of an asymptomatic disease
KR20030088035A (ko) * 2001-03-07 2003-11-15 바이오메리욱스 비.브이. 전사 기초한 증폭을 이용하는 dna의 증폭 및 검출 방법
US20050119198A1 (en) * 2002-02-08 2005-06-02 Peter Carmeliet Novel target to inhibit angiogenesis
US7252976B2 (en) * 2002-08-28 2007-08-07 Board Of Regents The University Of Texas System Quantitative RT-PCR to AC133 to diagnose cancer and monitor angiogenic activity in a cell sample

Also Published As

Publication number Publication date
EP1571225A1 (de) 2005-09-07
WO2005083123A1 (en) 2005-09-09
CA2558604A1 (en) 2005-09-09
EP1725679A1 (de) 2006-11-29
EP1725679B1 (de) 2009-06-03

Similar Documents

Publication Publication Date Title
ATE432997T1 (de) Therapieüberwachung für tumoren unter benutzung acc133 mrna
CA2735578C (en) Method of identifying risk factors for alzheimer's disease comprising tomm40 gene variants
ATE540319T1 (de) Verfahren für die bestimmung von fk506
WO2008069975A3 (en) Methods of using f-spondin as a biomarker for cartilage degenerative conditions
DE602004017426D1 (de) Benutzung von intronischen rna sequenzen zur quantifizierung der genexpression
WO2007126758A3 (en) Method and system for determining whether a drug will be effective on a patient with a disease
ES2530843T3 (es) Métodos basados en microARN para el diagnóstico de cáncer de páncreas
ATE423217T1 (de) Assays zur überwachung von krebspatienten auf grundlage der spiegel von analytenkomponenten des plasminogen-aktivator-systems in proben von körperflüssigkeiten
PE20120015A1 (es) Metodos y sistemas para predecir la respuesta de las celulas tumorales a un agente terapeutico
CY1113403T1 (el) Νεος βιοδεικτης για την παρακολουθηση της εξελιξης των νοσων και την εκτιμηση της αποτελεσματικοτητας των θεραπειων
SG156625A1 (en) Method for measuring resistance or sensitivity to docetaxel
WO2006055524A3 (en) Biomarkers for diagnosing schizophrenia and bipolar disorder
WO2007016367A3 (en) Neoplastic disease-related methods, kits, systems and databases
WO2006113245A3 (en) Methods for measuring glycan levels of proteins
BRPI0412110A (pt) genes regulados no cáncer ovariano como alvos prognósticos e terapêuticos
ATE454465T1 (de) In-vitro-verfahren zur identifizierung von verbindungen zur krebstherapie
BRPI0414365A (pt) composições, reagentes e kits para, e métodos de diagnosticar, monitorar e tratar obesidade e/ou diabetes
WO2007016532A3 (en) Mutations and polymorphisms of hdac4
WO2006012468A3 (en) Detection of oligonuleotides by dual hybridization
WO2004113574A3 (en) Methods for disease screening
WO2008145701A9 (en) Method for predicting the outcome of a critically ill patient
DE50313393D1 (de) Verfahren zur diagnose von entzündungserkrankungen und infektionen mittels bestimmung von lasp-1/ lap-1
DE602004027534D1 (de) Diagnostische verfahren für therapeutische verbindungen sowie verfahren zur überwachung der azathioprin-therapie
WO2009068423A3 (en) Method for predicting therapy responsiveness in basal like tumors
WO2007015113A3 (en) New protein isoforms of the pif-family and uses thereof

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties